Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma. Issue 2 (16th December 2020)

• Record Type: Journal Article
• Authors: Rosner, Samuel; Agrawal, Yuri; Sun, Daniel Q; Aygun, Nafi; Schollenberger, Megan D; Lipson, Evan; Naidoo, Jarushka
• Is Part Of: Journal for immunotherapy of cancer. Volume 8:Issue 2(2020)
• Publication Date: 2020-12-16
• Subjects: immunotherapy -- case reports -- melanoma; Cancer -- Immunotherapy -- Periodicals; Cancer -- Immunological aspects -- Periodicals; Tumors -- Immunological aspects -- Periodicals; Immunotherapy -- Periodicals; 616.99406105
• DOI: 10.1136/jitc-2020-001675
• Languages: English
• ISSNs: 2051-1426

Abstract

Abstract : Immune checkpoint inhibitors (ICIs) are associated with a range of organ-specific toxicities known as immune-related adverse events (irAEs). Immune-mediated ototoxicity from ICIs is poorly described. Herein, we describe the clinical presentation, diagnostic evaluation and management of six ICI-treated patients who developed immune-mediated ototoxicity, identified by a multidisciplinary immune-related toxicity team. This is the largest case series to date and identifies bilateral high-frequency hearing loss and tinnitus as the most common reported symptoms and can be associated with abnormal speech reception thresholds and word recognition ability on audiogram in select patients. We propose multidisciplinary evaluation of patients with suspected otologic irAEs including referral to otolaryngology, audiometry evaluation±magnetic resonance imaging for evaluation of suspected immune-mediated ototoxicity.